Primary regulatory
Wegovy prescribing information
FDA prescribing information for Wegovy.
U.S. Food and Drug AdministrationPublished 2025Accessed 2026-07-12
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-wegovy-label-2025
Source usage
Linked from 7 pages
Video audit
Mounjaro (tirzepatide): The newest diabetes and obesity medication
Video auditHow Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
Video auditOzempic is a game-changer. Here's how it works.
Video auditWhat Ozempic & Weight Loss Drugs Really Do to the Body
Video auditDoctors explain how Wegovy and Ozempic work | 60 Minutes
Video auditWhat Is a GLP-1 Agonist, and How Does It Work?
Video auditPros and Cons of GLP-1 Weight-Loss Drugs
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.